Patents by Inventor Mi-Yong Yun

Mi-Yong Yun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240078990
    Abstract: The present invention relates to a polyester sound absorption material having improved moldability and decreased weight and a method of manufacturing a molded product using the same, and more particularly to a polyester sound absorption material, which is capable of integrally molding a skin member and a sound absorption material using a felt including a polyester base fiber, a low-melting-point polyester adhesive fiber and a polyester hollow fiber, without the need to attach an additional sound absorption pad onto a skin member.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 7, 2024
    Inventors: Hong Mo Koo, Mi Jung Yun, Joon Yong Song, Hyun Dae Cho, Hyung Joon Youn, Jeong Wook Lee
  • Patent number: 8354386
    Abstract: A pharmaceutical composition for the treatment of malignant tumors comprising a human p31comet gene encoding protein represented by SEQ ID NO: 3 or 4 as an effective component is provided. The pharmaceutical composition can suppress cancer cell growth, induce apoptosis and kill cells by overexpressing p31comet in the solid malignant tumor cells. Therefore, the pharmaceutical composition can be effectively used for gene therapy.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: January 15, 2013
    Assignee: Korea Institute of Radiological & Medical Sciences
    Inventors: Kee-Ho Lee, Sang-Hoon Kim, Hyun-Jung Baek, Kyoung-Mi Juhn, Jae-Min Jeong, Yeun-Jin Ju, Bu-Yeo Kim, Eun-Ju Lee, Yong-Ho Ham, Hee-Chung Kwon, Mi-Yong Yun, Gil-Hong Park
  • Publication number: 20100292166
    Abstract: A pharmaceutical composition for the treatment of malignant tumors comprising a human p31comet gene encoding protein represented by SEQ ID NO: 3 or 4 as an effective component is provided. The pharmaceutical composition can suppress cancer cell growth, induce apoptosis and kill cells by overexpressing p31comet in the solid malignant tumor cells. Therefore, the pharmaceutical composition can be effectively used for gene therapy.
    Type: Application
    Filed: December 20, 2005
    Publication date: November 18, 2010
    Applicant: KOREA ATOMIC ENERGY RESEARCH INSTITUTE
    Inventors: Kee-Ho Lee, Sang-Hoon Kim, Hyun-Jung Baek, Kyoung-Mi Juhn, Jae-Min Jeong, Yeun-Jin Ju, Bu-Yeo Kim, Eun-Ju Lee, Yong-Ho Ham, Hee-Chung Kwon, Mi-Yong Yun, Gil-Hong Park